In Mexico, the acute ischemic stroke drugs market generated approximately USD 130.6 million in 2024 and is projected to grow at a healthy CAGR of around 10% through 2030, reaching roughly USD 231.5 millionA primary driver behind this growth is the rising burden of non‑communicable chronic diseases especially hypertension, diabetes and obesity leading to a greater incidence of ischemic stroke in both older and increasingly younger demographic groupsWith public awareness improving and government healthcare initiatives expanding, more patients are being directed toward acute stroke therapies, bolstering demand for thrombolytics, anticoagulants, and antiplatelet agents.
TABLE - Mexico Acute Ischemic Stroke Drugs Market Size & Forecast By Drug Class 2021-2033
Drug Class | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thrombolytics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Anticoagulant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Antiplatelet | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Neuroprotective Agent | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis